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Abstract Rapid diagnostic tests (RDTs) have transformed malaria diagnosis. The most prevalent
P. falciparum RDTs detect histidine-rich protein 2 (PfHRP2). However, pfhrp2 gene deletions
yielding false-negative RDTs, first reported in South America in 2010, have been confirmed in Africa
and Asia. We developed a mathematical model to explore the potential for RDT-led diagnosis to
drive selection of pfhrp2-deleted parasites. Low malaria prevalence and high frequencies of people
seeking treatment resulted in the greatest selection pressure. Calibrating our model against
confirmed pfhrp2-deletions in the Democratic Republic of Congo, we estimate a starting frequency
of 6% pfhrp2-deletion prior to RDT introduction. Furthermore, the patterns observed necessitate a
degree of selection driven by the introduction of PfHRP2-based RDT-guided treatment. Combining
this with parasite prevalence and treatment coverage estimates, we map the model-predicted
spread of pfhrp2-deletion, and identify the geographic regions in which surveillance for pfhrp2-
deletion should be prioritised.
DOI: https://doi.org/10.7554/eLife.25008.001
Introduction
Efforts to control malaria globally have made substantial progress in the last 15 years (World Health
Organization, 2015a). This progress reflects the impact made by reinvigorated political commit-
ment that has yielded a twenty-fold increase in international funding for the control and elimination
of malaria (World Health Organization, 2015a). The World Health Organisation (WHO) Global
Technical Strategy for Malaria 2016–2030 sets ambitious goals to further reduce incidence and mor-
tality rates by 90% by 2030 (World Health Organization, 2015b). Central to achieving these goals
is the need to test, treat and track all malaria (World Health Organization, 2010).
In sub-Saharan Africa (SSA), diagnostic testing of suspected malaria cases has risen from 36% to
60% between 2005 and 2014 (World Health Organization, 2015a). Microscopy was historically the
most common method for diagnosis; however rapid diagnostic tests (RDTs) accounted for 71% of all
diagnostic testing of suspected cases in 2014 (World Health Organization, 2015a). The most widely
used RDTs target histidine-rich protein 2 (HRP2), which is expressed by the Plasmodium falciparum
(Pf) specific gene pfhrp2, with over 85% of RDTs tested in the WHO Foundation for Innovative New
Diagnostics (FIND) Malaria RDT Evaluation Programme targeting PfHRP2 (World Health Organiza-
tion, 2012a).
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False-negative RDT results due to a partial or complete deletion of the pfhrp2 gene have been
reported in areas of South America since 2010, resulting in the recommendation against the use of
PfHRP2-based RDTs in these areas (Akinyi et al., 2013; Abdallah et al., 2015; Cheng et al., 2014).
These pfhrp2-deleted mutants may still possess a functioning pfhrp3 gene; however, the cross reac-
tivity between PfHRP2-based RDT antibodies and PfHRP3 epitopes is such that a positive result may
only occur at very high parasitaemia (Baker et al., 2005). Confirmed pfhrp2-deleted mutants are
rarer in Africa, with the first cases reported in Mali in 2012 (Koita et al., 2012). However, recently
confirmed occurrences in Ghana, (Amoah et al., 2016) Zambia, (Laban et al., 2015) the Democratic
Republic of Congo (DRC), (Parr et al., 2016) Rwanda (Kozycki et al., 2017) and Eritrea
(Berhane et al., 2017) (Table 1) have prompted the WHO to host Technical Consultations on
pfhrp2/3-deletions and to issue interim guidance for malaria control programs (World Health Orga-
nization, 2017; World Health Organization, 2016a; World Health Organization, 2016b). This
raises the concern that pfhrp2-deleted mutants may be selected for by RDT-guided treatment deci-
sions – which if confirmed would be one of the first example of selection of a pathogen through
diagnostic testing.
Here we use mathematical modelling to characterise the impact of introducing PfHRP2-based
RDTs on the emergence and spread of pfhrp2-deleted parasites. We adapt a previously published
transmission model (Griffin et al., 2016), incorporating the transmission of pfhrp2-deleted mutants
and the contribution of PfHRP3 cross-reactivity to identify settings in which the selective pressure
favouring pfhrp2-deleted strains is greatest. In addition, we conduct sensitivity analyses to character-
ise the influence of assumptions within our model concerning adherence to RDT-guided treatment
decisions, the use of microscopy-based diagnostic testing, fitness costs associated with the mutant
parasite and the impact of non-malarial fevers upon the selective advantage of pfhrp2 gene dele-
tions. We continue by using a nationally representative cross-sectional study of pfrhp2-deletion in
the DRC (Parr et al., 2016) to estimate the prevalence of pfhrp2-deleted mutants prior to RDT intro-
duction. This, in turn, allows us to map predicted geographical regions across SSA where pfhrp2-
eLife digest Since the turn of the millennium, a large increase in international funding has
helped to reduce the public health impact of malaria. The introduction of rapid diagnostic tests has
played a central role in these efforts, particularly in remote areas that are heavily affected by the
disease. These tests analyse human blood samples for specific proteins that are produced by malaria
parasites.
The most common rapid diagnostic tests for malaria detect a protein called HRP2, which is
produced by the deadliest malaria parasite, Plasmodium falciparum. Recently, however, cases have
emerged where the tests have failed to detect these malaria infections. The first occurred in South
America, and were found to be because some malaria parasites no longer possessed the gene that
produces HRP2. Since then, malaria parasites that lack this gene have been found in several
locations in Africa. This raises the question of whether using the tests favours the survival and spread
of parasites that cannot produce the HRP2 protein.
Using mathematical modelling techniques, Watson et al. now present evidence that suggests that
the use of HRP2-detecting rapid diagnostic tests over the past 10 years could have favoured the
evolution of malaria parasites that lack this protein. Furthermore, the models suggest that the
conditions that are most likely to cause such selection are places where malaria infections are not
common but people seek treatment at high rates.
Using this information, Watson et al. created a map of 160 locations in Africa most at risk of rapid
diagnostic test-driven selection against the gene that produces HRP2. Public health authorities could
use these maps to determine where they should more closely monitor malaria parasites to see if
they lack this gene.
Future genetic investigations will be required in the high-risk areas to confirm and refine the
predictions. The development of rapid diagnostic tests that detect other malaria proteins will also
be essential if malaria parasites that lack HRP2 continue to spread.
DOI: https://doi.org/10.7554/eLife.25008.002
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deletion surveillance should be focused. These mapped predictions are explored across a range of
estimates of the prevalence of pfhrp2-deleted mutants prior to RDT introduction.
Results
Using our newly adapted model incorporating the transmission of pfhrp2-deleted mutants, we first
explored the potential for RDT-guided treatment decisions to exert an evolutionary pressure on the
prevalence of the mutant. Figure 1 shows the predicted proportion of strains that are pfhrp2-
deleted within the population after 10 years.
Within all settings that explored different transmission intensities and starting frequencies of
pfhrp2-deletion, RDT introduction is predicted to increase the proportion of pfhrp2-deleted
mutants. The strength of selection is predicted to be greatest at low PfPR (Figure 1a); however, a
selective pressure is still predicted at both high PfPR and at low starting pfhrp2-deletion frequencies
(Figure 1b). The variance in the selection pressure exerted by RDTs is also predicted to be greatest
at low PfPR (Figure 1c). A more gradual but analogous trend is predicted in the proportion of the
population that were only infected with pfhrp2-deleted mutants (Figure 1d). The prevalence of
malaria within Figure 1a was also observed to increase after RDT introduction (Figure 1—figure
supplement 1), with the greatest increase in lower transmission settings resulting from untreated
infections due to false-negative RDT results.
Within the sensitivity analyses, a selective pressure is observed to exist at comparative fitness
costs of greater than 90% (see Figure 1—figure supplement 2), however below this the pfhrp2-
deletion allele is quickly lost. Both the introduction of additional diagnosis with microscopy-based
methods and non-adherence to RDT results decreased the selective pressure, slowing the rate of
pfhrp2-deletion emergence (see Figure 1—figure supplement 3). The introduction of non-malarial
fevers, however, increased the rate of pfhrp2-deletion emergence (see Figure 1—figure supple-
ment 4), even at 25% below the mean estimated rate of non-malarial fever. When these opposing
factors were combined, RDT introduction is still predicted to increase the proportion of pfhrp2-
deleted mutants (Figure 1—figure supplement 5).
The proportion of clinical cases seeking treatment (assumed here to be treated on the basis of an
RDT result) is also predicted to exert a strong selection pressure for pfhrp2-deletion (Figure 2). A
consistent relationship was seen across comparable PfPR ranges, with the lowest treatment seeking
rates (fT = 0.2) yielding the slowest increase in the proportion of infections due to only pfhrp2-
deleted mutants. Again, the lower PfPR categories show the greatest selection pressures for pfhrp2-
deletion, with treatment seeking rates >30% and PfPR <25% leading to 20% of infections due to
only pfhrp2-deleted mutants in fewer than five years (Figure 2a).
The selection pressure favouring pfhrp2-deletions is predicted to be weaker when PfHRP3 epito-
pes are assumed to cause positive RDT results (Figure 2b). In settings where PfHRP3 epitopes are
assumed to cause a positive RDT result in 25% of cases (" = 0.25), there are four fewer prevalence
categories that reach 20% of infections due to only pfhrp2-deleted mutants in fewer than five years.
A similar effect is observed in the mean final frequency of pfhrp2-deletion, with 64% frequency
recorded after 20 years when no PfHRP3 epitope effect is assumed in comparison to 56% when " is
equal to 0.25 (Figure 2—figure supplement 1).
To estimate the starting frequency of pfhrp2-deleted mutants, we used estimates of the propor-
tion of pfhrp2-deleted mutants from a national study in DRC (Parr et al., 2016) to calibrate the
model. The calibration incorporated both the PfPR levels and estimates of the treatment rates in the
26 Divisions Provinciales de la Sante´ (DPS) that would drive selection of the mutant. We estimate a
starting frequency of pfhrp2-deleted P. falciparum of 6% in the DRC prior to any introduction of
RDTs. The observed relationship between the proportion of infections due to pfhrp2-deleted
mutants and PCR PfPR among children 6–59 months of age (Figure 3a) displays a similar trend to
the simulations, however with a notably steeper increase at lower prevalence. Of note, the same
relationship was not predicted in the absence of selection pressure due to RDT-based treatments
(i.e. purely on the basis of the variation in monoclonal infections) (Figure 3b).
Finally, using the baseline frequency estimate of 6% prior to RDT introduction, we explored 1000
different prevalence and treatment seeking rates spanning the range of estimates of the PfPR
(Bhatt et al., 2015) and treatment levels across sub-Saharan Africa (SSA) in 2010 (Cohen et al.,
2012) (Figure 4—figure supplement 2). The model output was aligned with these estimates by first
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administrative units (Figure 4—figure supplement 1), which enabled us to project the potential
increase of the mutant strain and its impact on RDT-guided treatment (Video 1). Our results suggest
that 160 of 850 first-administrative regions may have over 20% of all infections due to only pfhrp2-
deleted mutants by 2016 (Figure 4c). These areas, which we term of ‘high HRP2 concern’, are largely
located in areas where PfPR2-10 in 2010 was less than 25% (Figure 4a). A number of other regions,
PCR PfPR All Ages PCR PfPR All Ages
Figure 1. Predicted increase in pfhrp2-deletion upon RDT introduction after 10 years. Graphs show the time
course of pfhrp2-deletion emergence under (a) different transmission intensities (10%, 25% and 60% PfPR) and 8%
starting frequency of pfhrp2-deletion prior to RDT introduction and under (b) different assumed starting
frequencies of pfhrp2-deletion prior to RDT introduction (2%, 8% and 12% starting frequency) and 25% PfPR. Five
years after RDT introduction, the proportion of strains that are pfhrp2-deleted (c), and the proportion of the
population that are infected with only pfhrp2-deleted mutants (d) is recorded. The dark grey dots denote
individual simulation runs with a LOESS regression fit shown in blue. Source data for Figure 1 is provided within
Figure 1—source data 1.
DOI: https://doi.org/10.7554/eLife.25008.004
The following source data and figure supplements are available for figure 1:
Source data 1. Effect of transmission intensity and pfhrp2-deletion starting upon pfhrp2-deletion emergence.
DOI: https://doi.org/10.7554/eLife.25008.010
Figure supplement 1. Impact of increase pfhrp2-deletion upon malaria prevalence.
DOI: https://doi.org/10.7554/eLife.25008.005
Figure supplement 2. Impact of pfhrp2-deletion fitness cost.
DOI: https://doi.org/10.7554/eLife.25008.006
Figure supplement 3. Impact of microscopy use and non-adherence to RDT results.
DOI: https://doi.org/10.7554/eLife.25008.007
Figure supplement 4. Impact of non-malarial fever.
DOI: https://doi.org/10.7554/eLife.25008.008
Figure supplement 5. Combined impact of model assumptions.
DOI: https://doi.org/10.7554/eLife.25008.009
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classified as ‘moderate HRP2 concern’ have high treatment rates, and hence potential selective pres-
sure, despite having comparatively higher transmission (Figure 4b). Our results also illustrate that
regions with low transmission may have low HRP2 concern if the frequency of people seeking treat-
ment is very low.
Discussion
Our results demonstrate that the key drivers of pfhrp2-deletion selection are low malaria transmis-
sion and a high frequency of people seeking treatment and being correctly treated on the basis of
diagnosis with a PfHRP2-based RDT. Based on Africa-wide estimates of parasite prevalence and
treatment-seeking behaviour at the time of RDT-introduction, we identified 160 first-administrative
units which we classify as ‘high HRP2 concern’. These are areas where the pfhrp2-deleted strain is
0.0 − 0.15
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0.8 − 1.0
0.2 0.3 0.4 0.5 0.6
P
fP
R
a
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0.6 − 0.65
0.65 − 0.7
0.7 − 0.75
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Figure 2. The predicted rate at which the population is only infected with pfhrp2-deleted mutants. The graphs
show the time in years after RDT introduction at which 20% of the population are only infected with pfhrp2-
deleted mutants up to a maximum follow-up time of 20 years post RDT introduction. PfHRP3 epitopes were
assumed to cause a positive RDT result in (a) 0% or (b) 25% of individuals only infected with pfhrp2-deleted
mutants. The plotted years represent the mean time grouped in each prevalence and treatment setting, with black
dots representing where 20% was reached in less than five years. Each simulation had a starting pfhrp2-deletion
frequency of 8% before RDT introduction. Source data for Figure 2 is provided within Figure 2—source data 1.
DOI: https://doi.org/10.7554/eLife.25008.011
The following source data and figure supplement are available for figure 2:
Source data 1. Years after RDT introduction at which 20% of the population are only infected with pfhrp2-deleted
parasites, with an assumed PfHRP3 epitope effect equal to 0% and 0.25%.
DOI: https://doi.org/10.7554/eLife.25008.013
Figure supplement 1. Frequency of pfhrp2-deletion after 20 years.
DOI: https://doi.org/10.7554/eLife.25008.012
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Figure 3. Simulated province level burden of pfhrp2-deleted mutants within the DRC, with an assumed probability
of a clinical case seeking treatment, who is only infected with pfhrp2-deleted mutants, producing a positive RDT
result (") equal to 0.25. In (a) the mean simulated proportion of children aged 6–59 months who are infected with
only pfhrp2-deleted mutants is shown in red. Each region had an assumed starting frequency of 6% pfhrp2-
deletion prior to RDT introduction in 2010 (2007 in North- and South-Kivu). The results in grey represent the
recorded burden from the DHS survey (Figure 3—source data 1), with both datasets fitted with a LOESS
regression. Error bars show the 95% confidence interval. In (b) the same simulation conditions were used as in (a)
however it is assumed that no selection pressure is exerted by the introduction RDTs, i.e. " = 1. Source data for
Figure 3 is provided within Figure 3—source data 1.
DOI: https://doi.org/10.7554/eLife.25008.014
The following source data and figure supplement are available for figure 3:
Source data 1. Estimates of the proportion of pfhrp2-deleted mutants from a national study in DRC.
Figure 3 continued on next page
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expected to increase in frequency over a relatively short timescale, and hence where further surveil-
lance efforts should be concentrated.
Our results are based on calibration to a large representative survey of malaria across DRC. Due
to its size and location in the centre of SSA, the DRC is arguably one of the most representative
countries for endemic malaria in Africa. That the model was able to predict the observed relationship
in the DRC, despite variability at a province level, provides support for the hypothesis that the vari-
ability in pfhrp2-deletion frequency with transmission is driven by selection. However, in contrast to
other reported surveys, the samples in this survey were primarily drawn from asymptomatic infec-
tions, and hence may not be representative of other reports of pfhrp2-deletion in symptomatic cases
with higher parasite density. However, it is interesting to note that our results show broad agree-
ment with published data sets from Zambia (Laban et al., 2015) and Ghana (Amoah et al., 2016)
(Table 1). In particular, our predictions confirm that the HRP2 concern would be greater in Ghana
than in Southern Zambia. However, one study in Senegal found a lower prevalence of pfhrp2-dele-
tion than we predict (Wurtz et al., 2013).
A key uncertainty in predicting the potential spread of pfhrp2-deletion due to RDT-induced selec-
tive pressure is the extent of use of, and adherence to, RDT results and the availability of appropri-
ate treatment. On the one hand, if adherence to RDT results is poor (for example, with patients who
show continued clinical symptoms of malaria in the absence of a positive test) or additional micros-
copy-based detection is used (Figure 1—figure supplement 3), if appropriate treatment is not avail-
able (for example, due to stock-outs), or if treatment is not fully curative (for example, due to patient
non-adherence, drug resistance or fake drugs) then the spread of these deletions will be slower than
predicted. On the other hand, in areas in which active case detection occurs, or in which treatment
is sought for non-malaria fevers (Figure 1—figure supplement 4), RDT-based treatment may also
selectively clear non-deleted asymptomatic infec-
tions and hence increase the rate of spread of
the deletion. However, when these factors, along
with potential fitness costs associated with
pfhrp2-deletion, were investigated together we
still observed an increase in pfhrp2-deletion (Fig-
ure 1—figure supplement 5), which showed a
similar rate of increase to that predicted by our
model. Further data on RDT usage and adher-
ence, as well as on non-malarial fevers and the
precise fitness cost of pfhrp2-deletion, however,
could help to refine mapping of areas of HRP2
concern.
A second uncertainty relates to the underlying
prevalence of the mutation prior to RDT introduc-
tion. There is considerable variability in the esti-
mates that have been measured both before and
after RDT introduction, and it is entirely plausible
that the presence of mutations could vary geo-
graphically at a range of spatial scales. However,
estimating this variation is difficult given the lack
Figure 3 continued
DOI: https://doi.org/10.7554/eLife.25008.016
Source data 2. Simulated proportion of children aged 6–59 months who are only infected with pfhrp2-deleted
parasites within the Democratic Republic of Congo, with an assumed PfHRP3 epitope effect equal to 0.25% and
1%, that is under no selection pressure.
DOI: https://doi.org/10.7554/eLife.25008.017
Figure supplement 1. Simulated province level burden of pfhrp2-deleted mutants within DRC, with an assumed
probability of a clinical case seeking treatment, who is only infected with pfhrp2-deleted mutants, producing a
positive RDT result (") equal to 0.
DOI: https://doi.org/10.7554/eLife.25008.015
Video 1. The projected increase in individuals who are
only infected with pfhrp2-deleted parasites, from 2010
to 2030, with an assumed starting frequency of 6%
pfhrp2-deletion, and an assumed PfHRP3 epitope
effect equal to 0.25%. The video relates directly to
Figure 4.
DOI: https://doi.org/10.7554/eLife.25008.025
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Figure 4. Predicted areas of HRP2 concern in comparison to recorded prevalence and treatment seeking rate, with an assumed probability of a clinical
case seeking treatment, who is only infected with pfhrp2-deleted mutants, producing a positive RDT result (") equal to 0.25. The graphs show (a) the
recorded malaria prevalence in children aged 2–10 by microscopy in 2010, (b) the frequency of people seeking treatment in 2010 and (c) the predicted
concern for the impact of pfhrp2-deleted mutants. In (c), high, moderate and slight risk represent >20% infection due to only pfhrp2-deleted mutants
by 2016, 2022 and 2030 respectively, and marginal risk represents <20% by 2030. In 2010, each region was assumed to have a starting frequency of 6%
pfhrp2-deletion. Source data for Figure 4 is provided within Figure 4—source data 1.
DOI: https://doi.org/10.7554/eLife.25008.018
The following source data and figure supplements are available for figure 4:
Figure 4 continued on next page
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of a sampling framework in reports mainly based on clinical cases and given the relatively small sam-
ple sizes. Thus our results should be interpreted not as predictions of the absolute levels of the gene
deletion, but rather indicative of geographical areas in which surveillance should be focused. Simi-
larly, these results should not be interpreted as predictions of the precise negative impact on malaria
prevalence as a result of increased gene deletions (Figure 1—figure supplement 1), but illustrative
of the potential impact of false-negative test results upon malaria prevalence and the importance of
alternative diagnostic methods (Figure 1—figure supplement 3). At the same time, further data col-
lated in the coming months and years can be incorporated to iteratively update and refine our
projections.
As with any modelling exercise, there are a number of important limitations. Firstly, we did not
capture seasonality or any fitness cost associated with pfhrp2-deletion. At a given transmission level,
highly seasonal locations are likely to have a lower frequency of pfhrp2-deletion in comparison to
regions with perennial transmission. Seasonality could however cause substantial bottlenecks which
may result in repetitive founder effects that could affect selection, resulting in either a decreased
chance of pfhrp2-fixation or an accelerated fixation if it occurred (Aguile´e et al., 2009). In simula-
tions incorporating a fitness cost the selection pressure was found to be considerably weaker (Fig-
ure 1—figure supplement 2). The exact fitness cost, despite being unknown, is likely subtle as our
modelled fitness penalty would cause the strain to be eliminated at less than 90% comparative fit-
ness. In addition, current theories concerning the role of PfHRP2 indicate a more minor role in heme
detoxification than previously thought. Strains lacking PfHRP2 have been shown to be viable
(Papalexis et al., 2001), with heme detoxification more dependent on the recently characterised
haem detoxification protein (HDP) (Jani et al., 2008). Furthermore, in South America the first cases
of pfhrp2-deleted P. falciparum were confirmed prior to the introduction of RDTs (Gamboa et al.,
2010). This suggests that these mutants may possess sufficiently high fitness such that the frequency
of pfhrp2-deletion is maintained in the absence of a selective advantage exerted through the use of
HRP2-based RDTs.
Secondly, our results depend on assumptions made regarding the contribution of PfHRP3 epi-
tope cross-reactivity and the potential for false-positive RDT results. We found that increased cross-
reactivity with PfHRP3 epitopes decreases selection for pfhrp2-deletion and was investigated due to
confirmed observations of PfHRP2-based RDTs detecting PfHRP3 epitopes at high parasitaemia
(Baker et al., 2010). In simulations with no epitope effect, the model predicts the pattern in DRC
well (Figure 3—figure supplement 1) and predicts a higher overall estimate of HRP2 concern (Fig-
ure 4—figure supplement 1), although the same regional patterns are identified (Figure 4—figure
supplement 2). Furthermore, false-positive RDT results would decrease the strength of the selection
pressure, with pfhrp2-monoclonal infections being treated. However, false-positivity rates observed
within round 6 of WHO RDT product testing were found to be low, with the median false-positive
rate on both clean negative samples and samples containing other infectious agents equal to 0%,
Figure 4 continued
Source data 1. Recorded malaria prevalence in children aged 2–10 by microscopy in 2010 (sourced from the Malaria Atlas mapping project [see Meta-
data - Datasets]), the frequency of people seeking treatment in 2010 (sourced from Cohen et al., 2012 [see Metadata – Datasets]) and the simulated
predicted concern for the impact of pfhrp2-deleted mutants, with an assumed PfHRP3 epitope effect equal to 0.25%.
DOI: https://doi.org/10.7554/eLife.25008.024
Figure supplement 1. Model malaria prevalence output against Malaria Atlas Project prevalence 2010 (Bhatt et al., 2015).
DOI: https://doi.org/10.7554/eLife.25008.019
Figure supplement 2. HRP2 Concern heat maps.
DOI: https://doi.org/10.7554/eLife.25008.020
Figure supplement 3. Predicted areas of HRP2 concern in comparison to recorded prevalence and treatment coverage with an assumed probability of
a clinical case seeking treatment, who is only infected with pfhrp2-deleted mutants, producing a positive RDT result (") equal to 0.
DOI: https://doi.org/10.7554/eLife.25008.021
Figure supplement 4. Impact of different assumptions about starting frequency of pfhrp2-deletion upon the geographical pattern of selection-driven
increase in pfhp2-deletion.
DOI: https://doi.org/10.7554/eLife.25008.022
Figure supplement 5. Years in which RDTs were used at community level in Sub-Saharan Africa.
DOI: https://doi.org/10.7554/eLife.25008.023
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and the overall false-positive rate on samples containing immunological factors equal to 0.9%
(World Health Organization, 2015c).
Thirdly, in the absence of systematic country introduction data, we assumed introduction of RDTs
in all countries from 2010 in accordance with the WHO recommendation of testing in 2010
(World Health Organization, 2010). The precise date from region to region is undoubtedly more
complex, however 2010 is a sensible estimate given the reported years at which RDTs were available
at the community level in SSA by the WHO (Figure 4—figure supplement 5) (World Health Organi-
zation, 2012b). However, the ratio of testing via microscopy versus RDT is likely to have decreased
over this period, and hence our estimate of RDT use (which our model assumes is 100% from intro-
duction) is likely too high. The sensitivity of the output to this parameter is demonstrated in the data
from the DRC, in which higher levels of pfhrp2-deletion are observed in Kivu, an area in which RDT
introduction likely occurred earlier than elsewhere in the country (Me´decins Sans Frontie`res, 2007).
Fourthly, extrapolating the starting frequency of pfhrp2-deletion strains from the DRC across the
rest of SSA is a clear oversimplification; however, in the absence of similar datasets, we feel it pro-
vides a reasonable first estimate. To assess the implications of this estimate, we also considered how
the pattern of geographical areas that we have recommended for priority surveillance changes under
different assumed starting frequencies of pfhrp2-deletion (Figure 4—figure supplement 4). Despite
the expected changes in the final frequency of pfhrp2-deletion in these settings, the overall pattern
of areas with the highest selection-driven increase in pfhrp2-deletion remains the same. A final limi-
tation is that we assumed that treatment rates and transmission of malaria remain constant from
2010. This is clearly not the case, with 30 countries in SSA reporting a decline in prevalence from
2010 to 2015 (Bhatt et al., 2015). These combined effects, however, would presumably cause an
increase in monoclonal infections and subsequent false-negative RDTs due to pfhrp2-deleted
parasites.
In summary, our modelling predicts that an increased emergence of pfhrp2-deleted mutants may
be explained by the introduction of testing by PfHRP2-based RDTs. If this is indeed the case, this
would be, to our knowledge, one of the first examples of the emergence of resistance of a pathogen
to a diagnostic test. The use of these RDTs will result in the greatest selection pressure in regions
that have low malaria transmission and a high frequency of RDT-based treatment of clinical cases.
Rapid and accurate diagnosis of P. falciparum infection, however, is essential for continued reduction
in malaria transmission. In light of this, it may be sensible for public health bodies who are respond-
ing to reports of pfhrp2 gene deletions to focus surveillance in the regions we have identified as hav-
ing a high HRP2 concern. This work should proceed alongside further improvement of non-HRP2-
based RDTs, such as those that detect lactate dehydrogenase, and the development of new alterna-
tive diagnostics.
Materials and methods
P. falciparum transmission model
An individual-level stochastic model was developed to simulate the transmission dynamics of Plas-
modium falciparum. The model is based upon previous modelling efforts (Griffin et al., 2016;
Griffin et al., 2014; Griffin et al., 2015), and is described in full here before describing the exten-
sions made with regards to PfHRP2 dynamics, and defining the parameters used and their sources.
The model is implemented as stochastic individual-based model with a fixed daily time step, incor-
porating the necessary delay terms where mentioned, which is described in greater detail later. In
overview, the transmission model considers people to exist in one of six infection states (Figure 5):
susceptible (S), clinical disease (D), clinically diseased and receiving treatment (T), asymptomatic
infection (A), protective state of prophylaxis (P), and subpatent infection (U).
Individuals begin life susceptible to infection (state S). At birth, individuals possess a level of
maternal immunity that decays exponentially over the first 6 months. Each day individual i is proba-
bilistically exposed to infectious bites governed by their individual force of infection (Li). Li is depen-
dent on their pre-erythrocytic immunity, biting rate (dependent on both their age and their
individual relative biting rate due to heterogeneous biting patterns in mosquitoes) and the mosquito
population’s size and infectivity. Infected individuals, after a latent period of 12 days (dE), develop
either clinical disease (state D) or asymptomatic infection (state A). This outcome is determined by
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their probability of acquiring clinical disease (f), which is dependent on their clinical immunity. Indi-
viduals that develop disease have a fixed probability (fT) of seeking treatment (state T), and a vari-
able probability ("i) that the clinical case yields a positive diagnostic result and subsequently receives
treatment. "i is dependent on the assumed role of PfHRP3 epitopes, and the strain profile of
infected individual i with respect to pfhrp2-deleted mutants. Treated individuals are assumed to
always recover, i.e. fully-curative treatment, and then enter a protective state of prophylaxis (state P)
at rate rT, before returning to susceptible at rate rS. Individuals that did not receive treatment
recover to a state of asymptomatic infection at rate rD. Asymptomatic individuals progress to a sub-
patent infection (stage U) at rate rA, before clearing infection and returning to susceptible at rate rU.
Additionally, superinfection is possible for all individuals in states D, A and U. Superinfected individu-
als who receive treatment will move to state T. Individuals who are superinfected but do not receive
treatment in response to the superinfection will either develop clinical disease, thus moving to state
D, or develop an asymptomatic infection and move to state A (except for individuals who were previ-
ously in state D, who will remain in state D).
The introduction of a fixed time step translates the waiting times at which individuals move from
one infection state to another into a daily probability that this event occurs, with the probability
drawn from the related exponential distribution. Thus the probability of a transition from state A to
state B with hazard rate l is given by:
S P
D
T
U
A
rA
rU
rP
rT
rD
(1- )(1- )
(1- )
.
fT 
.
(1-fT )
.
.
Figure 5. Transmission Model. Flow diagram for the human component of the transmission model, with dashed
arrows indicating superinfection. S, susceptible; T, treated clinical disease; D, untreated clinical disease; P,
prophylaxis; A, asymptomatic patent infection; U, asymptomatic sub-patent infection. All parameters are
described within Table 2.
DOI: https://doi.org/10.7554/eLife.25008.026
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Prob A ! Bð Þ: 1  exp  lð Þ
The set of state transitions for individuals and their associated hazard rates are given below.
Process Transition Hazard
Infection S fi I Li t   dEð Þ
Progression of untreated disease to asymptomatic infection D fi A rD ¼
1
dD
Progression of asymptomatic infection to subpatent infection A fi U rA ¼
1
dA
Progression of subpatent infection to susceptible U fi S rU ¼
1
dU
Progression of treated disease to uninfected prophylactic period T fi P rT ¼
1
dT
Progression from uninfected prophylactic period to susceptible P fi S rP ¼
1
dP
Super-infection from untreated clinical disease,
asymptomatic infection or subpatent infection
D fi I
A fi I
U fi I
Li t   dEð Þ
Here state I denotes an infection state which is not tracked but which leads to either clinical dis-
ease (D), treated clinical disease (T) or asymptomatic infection (A). In the original model the probabil-
ity of entering these states is determined by drawing a sequence of Bernoulli trials for each infected
individual as:
Prob Clinical Diseaseð Þ: Bernoulli fið Þ
Prob Treated Clinical Disease j Clinical Diseaseð Þ: Bernoulli fTð Þ
For our model here, in which treatment is guided by RDT-based diagnostics, we introduce. . .
Prob Treated Clinical Disease j Clinical Diseaseð Þ: Bernoulli fT"ið Þ
We assume that each person has a unique biting rate, which is the product of their relative age
dependent biting rate,  i, given by
 i að Þ ¼
Pn
i¼1 i að Þ
n
1  exp
 a
a0
 
and an assumed heterogeneity in biting patterns of mosquitoes, zi, which we assume persists
throughout their lifetime and is drawn from a log-normal distribution with a mean of 1,
log zið Þ~ N
 s2
2
;s2
 
where 1   is the relative biting rate at birth when compared to adults and a0 represents the
time-scale at which the biting rate increases with age. The product of these biting rates is subse-
quently used to calculate an individual’s entomological inoculation rate, hi, and subsequently their
force of infection, which are given by
hi ¼ akIMzi i
Li ¼ hibi
where ak is the daily rate at which a mosquito takes a blood meal, IM is the size of the infected
mosquito population, and bi is the probability of infection given an infectious mosquito bite.
The human population was assumed to have a maximum possible age of 100 years, with an aver-
age age of 21 years within the population yielding an approximately exponential age distribution
typical of sub-Saharan countries. When an individual dies, they are replaced with a new-born individ-
ual whose individual biting rate due to heterogeneity in biting patterns is drawn again from a log-
normal distribution with a mean of 1.
Watson et al. eLife 2017;6:e25008. DOI: https://doi.org/10.7554/eLife.25008 13 of 24
Research article Epidemiology and Global Health
Table 2. Parameters used within the human transmission and mosquito population models.
Parameter Symbol Estimate
Human infection duration (days)
Latent period dE 12
Patent infection dA 200
Clinical disease (treated) dT 5
Clinical disease (untreated) dD 5
Sub-patent infection dU 110
Prophylaxis following treatment dP 25
Treatment Parameters
Probability of seeking treatment if clinically diseased fT Variable
Probability of a clinical case seeking treatment, who is only infected with
pfhrp2-deleted mutants, producing a positive RDT result.
" 0 or 0.25
Infectiousness to mosquitoes
Lag from parasites to infectious gametocytes dg 12 days
Untreated disease cD 0.0680 day
 1
Treated disease cT 0.0219 day
 1
Sub-patent infection cU 0.000620 day
 1
Parameter for infectiousness of state A g1 1.824
Age and heterogeneity
Age-dependent biting parameter  0.85
Age-dependent biting parameter a0 8 years
Daily mortality rate of humans  0.000130
Variance of the log heterogeneity in biting rates s2 1.67
Immunity reducing probability of infection
Maximum probability due to no immunity b0 0.590
Maximum relative reduction due to immunity b1 0.5
Inverse of decay rate dB 10 years
Scale parameter IB0 43.879
Shape parameter kB 2.155
Duration in which immunity is not boosted uB 7.199
Immunity reducing probability of clinical disease
Maximum probability due to no immunity f0 0.791
Maximum relative reduction due to immunity f1 0.000737
Inverse of decay rate dCA 30 years
Scale parameter IC0 18.0237
Shape parameter kC 2.370
Duration in which immunity is not boosted uC 6.0635
New-born immunity relative to mother’s PM 0.774
Inverse of decay rate of maternal immunity dM 67.695
Immunity reducing probability of detection
Minimum probability due to maximum immunity d1 0.161
Inverse of decay rate dID 10 years
Scale parameter ID0 1.578
Shape parameter kD 0.477
Duration in which immunity is not boosted uD 9.445
Scale parameter relating age to immunity aD 21.9 years
Table 2 continued on next page
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Immunity and detection functions
We consider three stages at which immunity may impact transmission:
1. Pre-erythrocytic immunity, IB; reduction in the probability of infection given an infectious mos-
quito bite.
2. Acquired and Maternal Clinical Immunity, ICA and ICM respectively; reduction in the probability
of clinical disease given an infection due to the effects of blood stage immunity.
3. Detection immunity, ID; reduction in the probability of detection and a reduction in the
onward infectivity towards mosquitoes due to the effects of blood stage immunity.
Maternal clinical immunity is assumed to be at birth a proportion, PM , of the acquired immunity
of a 20 year-old and to decay at rate 1
dM
.
The probabilities of infection, detection and clinical disease are subsequently created by trans-
forming each immunity function by Hill functions. An individual’s probability of infection, bi; is given
by
bi ¼ b0 b1þ
1  b1
1þ IB
IB0
 kB
0
B@
1
CA
where b0 is the maximum probability due to no immunity, b0b1 is the minimum probability and
IB0 and kB are scale and shape parameters respectively.
An individual’s probability of clinical disease, fi, is given by
fi ¼f0 f1þ
1 f1
1þ ICAþICM
IC0
 kC
0
B@
1
CA
where f0 is the maximum probability due to no immunity, f1f0 is the minimum probability and
IC0 and kC are scale and shape parameters respectively.
An individual’s probability of being detected by microscopy when asymptomatic, qi;is given by
qi ¼ d1þ
1  d1
1þ ID
ID0
 kD
fD
0
B@
1
CA
where d1 is the minimum probability due to maximum immunity, and ID0 and kD are scale and
shape parameters respectively. fD is dependent only on an individual’s age is given by
dfD
da
¼ 1 
1  fD0
1þ a
aD
 gD
where fD0 represents the time-scale at which immunity changes with age, and aD and gD are scale
Table 2 continued
Parameter Symbol Estimate
Time-scale at which immunity changes with age fD0 0.00706
Shape parameter relating age to immunity gD 4.818
PCR detection probability parameters state A aA 0.757
PCR detection probability parameters state U aU 0.186
Mosquito Population Model
Daily mortality of adults M 0.132
Daily biting rate ak 0.307
Extrinsic incubation period dEM 10 days
DOI: https://doi.org/10.7554/eLife.25008.028
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and shape parameters respectively. Lastly, aA and aU are parameters that determine the probability
that an individual in states A and U are detectable by PCR, which are given by qaA and qaU
respectively.
The contribution made by each infected individual towards the overall infectiousness of the
human population towards mosquitoes is proportional to both their infectious state and their proba-
bility of detection, with a lower probability of detection assumed to correlate with a lower parasite
density. Individuals who are in state D (clinically diseased), state U (sub-patent infection) and state T
(receiving treatment) contribute cD, cU and cT . In state A, infectious contribution, cA; is given by cU þ
cD   CUð Þq
gI where q is the probability of being detected by microscopy when asymptomatic, and gI
is a parameter that controls how quickly infectiousness falls within the asymptomatic state.
Stochastic model equations
Given the definitions above, the full stochastic individual-based human component of the model can
be formally described by its Kolmogorov forward equations. As before, let iindex individuals in the
population. Then the state of individual i at time t is given by j; k; tk; l; tl;m; tm; cm; a; tf g, where a is
age, j represents infection status (S;D;A;U; T or P), k is the level of infection-blocking immunity and
tk is the time at which infection blocking immunity was last boosted. Similarly, l and tl denote the
level and time of last boosting of clinical immunity, respectively, while m and tm do likewise for para-
site detection immunity, and cm represents maternal immunity. Let dp;q denote the Kronecker delta
(dp;q ¼ 1 if p ¼ q and 0 otherwise) and d xð Þ denote the Dirac delta function. Defining
Pi(j; k; tk; l; tl;m; tm; cm; a; t) as the probability density function for individual i being in state
j; k; tk; l; tl;m; tm; cm; a; tf g at time t, the time evolution of the system is governed by the following for-
ward equation:
qPi j;k; tk; l; tl;m; tm;cm;a; tð Þ
qt
þ
qPi j;k; tk; l; tl;m; tm;cm;a; tð Þ
qa
¼ (1)
dj;S rPPi P;k; tk; l; tl;m; tm;cm;a; tð Þþ rUPi U;k; tk; l; tl;m; tm;cm;a; tð Þ½  (2)
þdj;A rDPi D;k; tk; l; tl;m; tm;cm;a; tð Þ½  (3)
þdj;U rAPi A;k; tk; l; tl;m; tm;cm;a; tð Þ½  (4)
þdj;P rTPi T;k; tk; l; tl;m; tm;cm;a; tð Þ½  (5)
þ 1  bið Þhi t  dEð Þ dj;Sþ dj;Dþ dj;Aþ dj;U
 
Ob Pi j;k; tk; l; tl;m; tm;cm;a; tð Þ (6)
þbihi t  dEð Þ dj;A 1 fið Þþ dj;Dfi 1  "ifTð Þþ dj;Tfi"ifT
 
Ob Oc Ob 
P
j
02 S;A;Uf gPi j
0
;k; tk; l; tl;m; tm;cm;a; t
   (7)
þbihi t  dEð Þ þdj;Dfi 1  "ifTð Þþ dj;Tfi"ifT
 
Ob Oc Od Pi D;k; tk; l; t;m; tm;cm;a; t
   (8)
þ rBk
q
qk
þ rCAl
q
ql
þ rIDm
q
qm
þ rCMcm
q
qcm
 
Pi j;k; tk; l; tl;m; tm;cm;a; tð Þ (9)
þ d að Þd tk þTbig
  
d tlþTbig
  
d tmþTbig
  
dj;Sdk;0dl;0dm;0
j
0
P
Pi j
0;k; tk; l; tl;m; tm;cm;a; tð Þ (10)
 ½þ rPdj;Pþ rUdj;U þ rDdj;Dþ rAdj;Aþ rTdj;P
þhi t  dEð Þ½dj;Sþ dj;Dþ dj;Aþ dj;U Pi j;k; tk; l; t;m; tm;cm;a; t
   (11)
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Here Ob, Oc and Od are commutative integral operators with the following action on an arbitrary
density f j;k; tk; l; tl;m; tm;cm;a; tð Þ:
Ob  f ¼ d t  tkð Þ
Z
¥
0
f j;k  1; t  uB  t; l; tl;m; tm;cm;a; tð Þdtþ 
t  tk
uB
 
f j;k; tk; l; tl;m; tm;cm;a; tð Þ
Oc  f ¼ d t  tlð Þ
Z
¥
0
f j;k; tk; l  1; t  uC   t;m; tm;cm;a; tð Þdtþ 
t  tl
uC
 
f j;k; tk; l; tl;m; tm;cm;a; tð Þ
Od  f ¼ d t  tmð Þ
Z
¥
0
f j;k; tk; l; tl;m  1; t  uD  t;cm;a; tð Þdtþ 
t  tm
uD
 
f j;k; tk; l; tl;m; tm;cm;a; tð Þ:
Finally,  xð Þ is an indicator function such that  xð Þ ¼ 1 if x<1 and 0 otherwise. These functions allow
the fixed periods of time in which immunities are not boosted after a previous boost to be included
within the stochastic equations, while also allowing superinfection events to be incorporated.
For simulation, a discrete time approximation of this stochastic model was used, with a time-step
of 1 day. For each individual k, l and m are set to zero at birth, while tk, tl and tm are set to a large
negative value  Tbig (to represent never having been exposed or infected). Each immunity term
increases by 1 for an individual whenever that individual receives an infectious bite (k), or is infected
(l and mÞ, if the previous boost to k, l and m occurred more than uB, uC and uD days earlier, respec-
tively. Immunity levels decay exponentially at rate rB, rCA and rID, where rB, rCA and rID are equal
to 1
dB
, 1
dCA
and 1
dID
respectively.
The stochastic model equations detailed above can be explained as follows. The first line is the
total time derivative of Pi(j; k; tk; l; tl;m; tm; cm; a; t). The next four lines describe the flows into states S,
A, U and P due to progression through infection states.
The sixth line describes exposure to malaria that boosts pre-erythrocytic immunity but does not
lead to an infection. The first term within the commutative integral operator Ob here considers the
density of individuals who are in immunity class k-1 and whose last boost to their pre-erythrocytic
immunity was more than uB days earlier, and thus will be flowing into the considered density, k, from
a lower pre-erythrocytic immunity. The second term in the integral will equate to 1 when considering
individuals who are in immunity class k and whose last boost to their pre-erythrocytic immunity was
less than uB days earlier and thus do not see their immunity boosted and hence remain in class k.
This is needed to represent the current density of individuals in the considered density. There is no
term for individuals in immunity class k whose last boost to their pre-erythrocytic immunity occurred
more than uB days earlier as they would move out of the considered density (into class k + 1) and
hence the indicator function will equate to 0 for these individuals.
The seventh line describes exposure events occurring to individuals in states S, A and U which do
result in patent (blood-stage) infection, resulting in transition into states A, D or T. The force of infec-
tion acting on the density in state D is not included here but rather in the eighth line since these indi-
viduals may only move to states T or D and not A. In both the seventh and eighth lines, the
commutative operators here function as described earlier. This tracks the density of individuals in
immunity states one lower whose last boost to any of the three immunity types occurred a sufficient
number of days earlier to flow into the considered density, while also considering the individuals
already at the same immunity as the considered density to remain in their current combined infec-
tion/immunity state (when the indicator function equates to 1) or to move to a new infection/immu-
nity state (when the indicator function equates to 0).
The ninth line (effectively a first order wave equation) represents deterministic exponential decay
of the four different types of immunity. The tenth line represents the birth process. We assume a
constant population size, so upon death, individuals flow into the state with no immunity and last
immunity boosting times are set to  Tbig, chosen to be sufficiently early to allow immediate boosting
upon exposure to infection (i.e. zero immunity other than maternal at birth). The last line shows the
removal of individuals from the population through death, balancing the inflow from the previous
line.
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Mosquito population dynamics
The adult stage of mosquito development was modelled in a compartmental formulation. Suscepti-
ble adult mosquitoes (SM) become infected at a rate which is proportional to the infectiousness of
the human population lagged by dg days, which represents the delay from emergence of asexual
blood-stage parasites to sexual gametocytes that contribute towards onward infectivity. The force of
infection towards mosquitoes on a given day, LM ; is represented by the sum of the contributions
from each infected human, delayed by dg, towards the overall infectiousness of the human popula-
tion, which is given by
LM¼
ak
N
PSD
i¼1
zi icDþ
PST
i¼1
zi icTþ
PSA
i¼1
zi icAþ
PSU
i¼1
zi icU
 
t dgð Þ
Infected mosquitoes then pass through a latent stage (EM) of duration dEM ; before becoming
infectious to humans (IM). Infectious mosquitoes remain infectious until they die. The differential
equations governing the adult stage of mosquitoes are given by
dSM
dt
¼ MMv MSM  LMSM
dEM
dt
¼LMSM MEM LM t dEMð ÞSM t dEMð Þexp
 MdEM
dIM
dt
¼LM t dEMð ÞSM t dEMð Þexp
 MdEM M IM
where M is the daily death rate of adult mosquitoes, and Mv is the total mosquito population, i.e.
SM þEM þ IM .
PfHRP2 dynamics
Individuals that are newly infected receive either a pfhrp2-deleted mutant or a wild type, determined
probabilistically by the ratio of pfhrp2-deleted mutants in the contribution to onwards infectiousness
governed by the human infectious population delayed by dEM. An individual with clinical disease
(state D), who possesses an equal number of wild type and pfhrp2-deleted mutants will for example
contribute ½cD to both the wild type and the mutant profile of the onwards infectiousness to mos-
quitos. In simulations incorporating a fitness cost associated with pfhrp2-deletion the contribution
terms (cD, cT, cA and cU) required to calculate the contribution to the human infectious reservoir
made by the deletion strains are comparatively decreased relevant to the wild type strains in order
to represent an assumed decrease in parasitaemia and onward transmission. This effect would also
capture if the pfhrp2-deleted strain is comparatively less fit within the mosquito. This would be of
importance when considering blood meals taken by mosquitoes feeding on polyclonally infected
individuals, in which we would expect the fitter wild-type parasite to be probabilistically more likely
to be onwardly transmitted.
If a newly infected individual is only infected with pfhrp2-deleted mutants the probability that
they enter the treated class is "fT , where " is equal to the cross reactivity contribution of PfHRP3 epit-
opes. If, however, they contain any wild type strains, " is assumed to always equal 1. Additionally, if
a subpatent individual is superinfected resulting in clinical disease, " is assumed to equal the cross
reactivity contribution of PfHRP3 epitopes if the acquired strain from superinfection is pfhrp2-
deleted. Analogously, " is assumed to always equal 1 if the acquired strain was wild type. This is to
reflect the inability of RDTs to detect any of the strains that were previously present within the sub-
patent individual.
Individuals that clear infection lose all strains, and infected individuals clear a random strain at
rate nrC, where n is the total number of strains and rC is the rate at which one strain is cleared in a
monoinfected individual, that is 1
dA þ dU
. This introduces a carrying capacity on the number of strains
an individual can be infected with, which scales with the transmission intensity. The multiplicity of
infection and strain profile of an infected individual have no effect on the disease outcome except
when the use of RDTs is introduced.
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Model code availability and parameter values
The model code was developed using the R language (RRID:SCR_001905), (R Core Team, 2016)
and is available with shape files and plotting scripts through an open source MIT license at https://
github.com/OJWatson/hrp2malaRia (Watson, 2017). A copy is archived at https://github.com/elifes-
ciences-publications/hrp2malaRia. The model is also written out in full as a pseudocode model using
mathematical syntax (Supplementary file 1). Parameter estimates used within the model were taken
from Griffin et al. (2014), (2015) and (Griffin et al., 2016) however have been included in Table 2
for clarity.
Characterising the epidemiological and clinical drivers of selection for
pfhrp2-deletion
The rate of pfhrp2-deleted mutant emergence after the introduction of RDTs was examined across a
range of malaria transmission intensities (10%, 25% and 60% parasite prevalence across all ages
[PfPR]) and starting proportions of pfhrp2-deleted mutants (2%, 8% and 12% mutants). For all simu-
lations conducted, the proportion of clinically diseased cases seeking treatment was equal to 40%
(fT = 0.4). In all simulations ten stochastic realisations of 100,000 individuals were simulated for 60
years to reach equilibrium first, before exploring different parameter settings. RDTs were then intro-
duced and the proportion of strains that are pfhrp2-deleted recorded over the following 10 years.
The effect of transmission intensities (0%–90% PfPR) was explored further by recording both the pro-
portion of strains that are pfhrp2-deleted and the proportion of individuals only infected with
pfhrp2-deleted mutants at 5 years after RDT introduction. In these simulations PfHRP3 epitopes
were assumed to never yield a positive RDT result (" = 0.0).
The rate of emergence was further examined under different assumptions about the proportion
of people seeking treatment (fT = 0.2–0.6), recording the time taken for the proportion of individuals
only infected with pfhrp2-deleted mutants to reach 20%. For each simulation we assumed 8% of
strains carried pfhrp2-deleted mutants prior to RDT introduction. We also considered the role that
PfHRP3 antigens may have in the performance of PfHRP2-based RDTs, assuming that 25% of individ-
uals only infected with pfhrp2-deleted mutants receive treatment due to the presence of PfHRP3
epitopes (" = 0.25), based on an estimate of PfHRP2-based RDT cross-reactivity (Baker et al., 2005).
A series of analyses were additionally conducted to characterise the impact of a number of
assumptions within the model. These sensitivity analyses were conducted at 20% PCR PfPR across all
ages, with the proportion of clinically diseased cases seeking treatment equal to 40% (fT = 0.4), and
an assumed starting frequency of pfhrp2-deletion equal to 10%. As before, in all simulations ten sto-
chastic realisations of 100,000 individuals were simulated for 60 years to reach equilibrium first,
before exploring different parameter settings.
We initially assessed the impact upon the strength of selection of a range of assumed compara-
tive fitness costs associated with pfhrp2-deletion (5%–100%). Secondly, we explored the impact on
selection of introducing additional microscopy-based diagnosis, occurring in 30% of cases in align-
ment with the 71% use of RDTs in 2014 (World Health Organization, 2015a), with and without an
assumed non-adherence to RDT results in 10% of cases in alignment with estimated improving levels
of adherence to RDT results (D’Acremont et al., 2013). Lastly, we investigated the impact of non-
malarial fevers (NMF), introducing an estimate for the annual NMF rate. This estimate was sourced
by first finding household Demographic Health Surveys in SSA that surveyed whether individuals had
been previously sick with a fever in the last 2 or 4 weeks and if and where they sought treatment for
that fever. The resultant six surveys (Institut de Statistiques et d’E´tudes E´conomiques du Burundi
- ISTEEBU et al., 2013), (Institut de Statistiques et d’E´tudes E´conomiques du Burundi - ISTEEBU
et al., 2013) Liberia (2009 [National Malaria Control Program - NMCP/Liberia, Ministry of Health
and Social Welfare/Liberia et al., 2012] and 2011 [National Malaria Control Program - NMCP/
Liberia, Ministry of Health and Social Welfare et al., 2009]), Mali (2010) and Nigeria (2010
[National Population Commission - NPC/Nigeria et al., 2012] and 2015 [National Malaria Elimina-
tion Programme - NMEP/Nigeria et al., 2016]) were then subset by those that had sufficiently rep-
resentative fever data across all ages, which yielded five surveys with Mali failing to be sufficiently
representative at higher age ranges. The survey from Burundi was chosen for further analysis as both
surveys from Liberia and Nigeria reported substantial treatment sought from drug peddlers and
drug hawkers respectively, complicating inference on the clinical outcome of any treatment sought
Watson et al. eLife 2017;6:e25008. DOI: https://doi.org/10.7554/eLife.25008 19 of 24
Research article Epidemiology and Global Health
for the fever. From this survey an age-bracketed annual rate of fever that led to treatment being
sought was calculated, with smaller age brackets used at younger ages to capture the rapid change
in fever rates at younger ages. This annual estimate was then scaled by 57% to represent the likely
NMF rate, as estimated from a large scale estimate across Africa (Gething et al., 2010). We subse-
quently incorporated this rate to explore the impact of NMF upon selection. Within these simula-
tions, we assume that individuals currently treated or in prophylaxis will not receive further
antimalarial treatment when presenting with a NMF. Susceptible and subpatent individuals who seek
treatment due to a NMF will only receive treatment due to non-adherence to test results. Lastly,
asymptomatic and diseased individuals who seek treatment due to a NMF will always receive treat-
ment, unless they are monoinfected with pfhrp2-deleted parasites in which case they will only be
treated due to potential PfHRP3 epitope contributions, non-adherence to RDT results or if they were
diagnosed with microscopy-based diagnosis.
Estimating the starting frequency and geographic spread of pfhrp2-
deletion
To estimate the current and future proportion of pfhrp2-deleted mutants across SSA, we require a
starting frequency of pfhrp2-deletion. We used estimates of the proportion of pfhrp2-deleted
mutants (Parr et al., 2016) from the 2013–2014 DRC Demographic and Health Survey (DHS)
(Meshnick et al., 2015) to infer the starting frequency before RDTs were introduced in 2010–2011,
(Meshnick et al., 2015) using the weighted PCR prevalence of malaria in children aged 6–59 months
(PCR PfPR 6–59 months) and the reported frequency of people seeking treatment in the 26 Divisions
Provinciales de la Sante´ (DPS). The DHS survey was a nationally representative cross-sectional study
of 7137 children aged 6–59 months and 783 subjects with RDT-/PCR+ results were tested using PCR
assays to detect and confirm pfhrp2-deletion.
We explored 50 starting frequencies between 0.1%–10%, with an assumed probability of a clinical
case seeking treatment, who is only infected with pfhrp2-deleted mutants, producing a positive RDT
result (") equal to 0.25. RDTs were assumed to be introduced in 2010 except for North- and South-
Kivu where the use of RDTs occurred from 2007 in the refugee camps. (Me´decins Sans Frontie`res,
2007; United Nations High Commissioner for Refugees, 2013) For each starting frequency, ten
stochastic realisations of 100,000 individuals were simulated for each DPS at malaria prevalence lev-
els aligned to the observed weighted PCR prevalence of malaria in children aged 6–59 months for
these provinces. These simulations were run for 60 years prior to the introduction of RDTs to ensure
equilibrium was reached. The output from each set of simulations at a given starting frequency was
smoothed using a local regression (LOESS) model, and the starting frequency identified as the set of
simulations with the smallest residual sum of squares when compared to the recorded relationship
from the DHS survey. It is important to highlight that due to the non-spatial nature of the model,
each geographical region simulated occurs independently to neighbouring regions, i.e. there is no
spatial spread of parasites between regions. Additionally, novel mutation emergence was not mod-
elled explicitly and thus stochastic loss of the pfhrp2-deletion genotype would always yield a final
pfhrp2-deletion frequency of 0%.
The estimated starting frequency was then used to simulate trends in the prevalence of pfhrp2-
deleted mutants across SSA, exploring a range of treatment coverages and transmission intensities,
with " = 0.25. These simulations considered populations of 100,000 individuals that were simulated
for 20 years from 2010 to 2030, with the introduction of RDTs assumed across all regions in 2010.
These outputs were matched to the mean microscopy-based PfPR in 2–10 year olds (PfPR2-10) in
2010 by first administrative unit and estimates of the proportion of cases seeking treatment from
Table 3. HRP2 classifiers used in sub-Saharan Africa mapping assuming RDT introduction in 2010.
Proportion of population only infected with pfhrp2-deleted mutants Concern classifier
>20% by 2016 High
>20% by 2022 Moderate
>20% by 2030 Slight
<20% by 2030 Marginal
DOI: https://doi.org/10.7554/eLife.25008.030
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previously modelled estimates using the DHS and the Malaria Indicator Cluster Surveys
(Cohen et al., 2012). The time taken for the proportion of infections due to only pfhrp2-deleted
mutants to reach 20% was recorded and classified to map areas of HRP2 concern under four qualita-
tive classifications shown in Table 3.
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